IL255120B - A pharmaceutical preparation containing 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one in the form of a spray-dried or miniaturized dispersion and its use for the treatment of cancer - Google Patents
A pharmaceutical preparation containing 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one in the form of a spray-dried or miniaturized dispersion and its use for the treatment of cancerInfo
- Publication number
- IL255120B IL255120B IL255120A IL25512017A IL255120B IL 255120 B IL255120 B IL 255120B IL 255120 A IL255120 A IL 255120A IL 25512017 A IL25512017 A IL 25512017A IL 255120 B IL255120 B IL 255120B
- Authority
- IL
- Israel
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- pharmaceutical composition
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000010922 spray-dried dispersion Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL255120A0 IL255120A0 (en) | 2017-12-31 |
| IL255120B true IL255120B (en) | 2021-03-25 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255120A IL255120B (en) | 2015-04-22 | 2017-10-18 | A pharmaceutical preparation containing 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one in the form of a spray-dried or miniaturized dispersion and its use for the treatment of cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (OSRAM) |
| EP (1) | EP3285770A4 (OSRAM) |
| JP (1) | JP2018513863A (OSRAM) |
| KR (1) | KR20170139119A (OSRAM) |
| CN (1) | CN107613981A (OSRAM) |
| AR (1) | AR104340A1 (OSRAM) |
| AU (1) | AU2016252992A1 (OSRAM) |
| BR (1) | BR112017022691A2 (OSRAM) |
| CA (1) | CA2983446C (OSRAM) |
| CL (1) | CL2017002679A1 (OSRAM) |
| CO (1) | CO2017011482A2 (OSRAM) |
| EA (1) | EA201792317A1 (OSRAM) |
| EC (1) | ECSP17071545A (OSRAM) |
| HK (1) | HK1243948A1 (OSRAM) |
| IL (1) | IL255120B (OSRAM) |
| MX (2) | MX390077B (OSRAM) |
| PE (1) | PE20180036A1 (OSRAM) |
| PH (1) | PH12017501933A1 (OSRAM) |
| SG (1) | SG11201708627TA (OSRAM) |
| TW (1) | TW201642860A (OSRAM) |
| WO (1) | WO2016172618A1 (OSRAM) |
| ZA (1) | ZA201707186B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
| EP3532059B1 (en) * | 2016-10-27 | 2022-01-26 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
| US11566004B2 (en) * | 2018-07-23 | 2023-01-31 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| US20220265618A1 (en) * | 2021-02-22 | 2022-08-25 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| SG11201602996RA (en) * | 2013-10-18 | 2016-05-30 | Celgene Quanticel Res Inc | Bromodomain inhibitors |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX390077B (es) | 2025-03-20 |
| TW201642860A (zh) | 2016-12-16 |
| CO2017011482A2 (es) | 2018-01-31 |
| AU2016252992A1 (en) | 2017-11-09 |
| KR20170139119A (ko) | 2017-12-18 |
| US20160310423A1 (en) | 2016-10-27 |
| ECSP17071545A (es) | 2017-12-01 |
| NZ736630A (en) | 2024-03-22 |
| PH12017501933A1 (en) | 2018-03-19 |
| JP2018513863A (ja) | 2018-05-31 |
| AR104340A1 (es) | 2017-07-12 |
| MX2017013501A (es) | 2018-02-09 |
| MX2020010899A (es) | 2022-02-15 |
| CA2983446C (en) | 2024-04-09 |
| WO2016172618A1 (en) | 2016-10-27 |
| ZA201707186B (en) | 2019-01-30 |
| IL255120A0 (en) | 2017-12-31 |
| EP3285770A4 (en) | 2018-10-31 |
| EA201792317A1 (ru) | 2018-03-30 |
| CL2017002679A1 (es) | 2018-05-25 |
| PE20180036A1 (es) | 2018-01-09 |
| CA2983446A1 (en) | 2016-10-27 |
| MX377159B (es) | 2025-03-07 |
| HK1243948A1 (zh) | 2018-07-27 |
| EP3285770A1 (en) | 2018-02-28 |
| CN107613981A (zh) | 2018-01-19 |
| BR112017022691A2 (pt) | 2018-07-17 |
| SG11201708627TA (en) | 2017-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255120B (en) | A pharmaceutical preparation containing 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one in the form of a spray-dried or miniaturized dispersion and its use for the treatment of cancer | |
| PT3717471T (pt) | Novos compostos e composições farmacêuticas dos mesmos para o tratamento de doenças | |
| LT3394030T (lt) | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu | |
| LT3350157T (lt) | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| IL271807A (en) | New compounds and their pharmaceutical preparations for the treatment of leprosy | |
| IL256684B (en) | Medicinal compounds and preparations for the treatment of social disorders and substance use disorders | |
| IL247721A0 (en) | Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors | |
| SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| EP3297640A4 (en) | Pharmaceutical co-crystal composition and use thereof | |
| BR112018004065A2 (pt) | Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos | |
| IL273339A (en) | Griseofulbin compound and its medical use | |
| PL3129378T3 (pl) | Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| EP3167893A4 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
| PL3290051T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| GB201718475D0 (en) | Pharmaceutical composition for treatment of depression and preparation method thereof | |
| HUE065421T2 (hu) | Nazális adagolású rifampicint tartalmazó gyógyszerészeti készítmény demencia kezelésére | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| IL271875A (en) | Preparations containing totarol and their use | |
| IL253788A0 (en) | Raccadotril pharmaceutical preparations | |
| EP3219323B8 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis c | |
| PL3204000T3 (pl) | Pochodne karboksylanów fenyloketonów i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |